Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium

Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic leukemia; it is US Food and Drug Administration approved for this indication....

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanski, Heather E., Eaton, Anne, Baggott, Christina, Rossoff, Jenna, Verneris, Michael R., Prabhu, Snehit, Pacenta, Holly L., Phillips, Christine L., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, M. Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Fabrizio, Vanessa A., Chinnabhandar, Vasant, Goksenin, A. Yasemin, Curran, Kevin J., Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979765/
https://www.ncbi.nlm.nih.gov/pubmed/35938863
http://dx.doi.org/10.1182/bloodadvances.2022007246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979765/
https://www.ncbi.nlm.nih.gov/pubmed/35938863
http://dx.doi.org/10.1182/bloodadvances.2022007246

Ejemplares similares